Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Candel Therapeutics (CADL) EBT Margin (2020 - 2023)

Historic EBT Margin for Candel Therapeutics (CADL) over the last 4 years, with Q4 2023 value amounting to 119.24%.

  • Candel Therapeutics' EBT Margin rose 252839900.0% to 119.24% in Q4 2023 from the same period last year, while for Dec 2023 it was 1299.23%, marking a year-over-year increase of 270967400.0%. This contributed to the annual value of 1444.74% for FY2024, which is 1455100.0% down from last year.
  • As of Q4 2023, Candel Therapeutics' EBT Margin stood at 119.24%, which was up 252839900.0% from 1349.48% recorded in Q3 2023.
  • Candel Therapeutics' 5-year EBT Margin high stood at 1565.02% for Q1 2023, and its period low was 29551.61% during Q1 2022.
  • Its 4-year average for EBT Margin is 15260.68%, with a median of 17148.39% in 2021.
  • In the last 5 years, Candel Therapeutics' EBT Margin tumbled by -172096800bps in 2021 and then surged by 311166400bps in 2023.
  • Candel Therapeutics' EBT Margin (Quarter) stood at 19600.0% in 2020, then fell by -28bps to 25003.23% in 2021, then dropped by -2bps to 25403.23% in 2022, then soared by 100bps to 119.24% in 2023.
  • Its EBT Margin was 119.24% in Q4 2023, compared to 1349.48% in Q3 2023 and 1517.08% in Q2 2023.